Vaseghi Maghvan Padina, Jeibouei Shabnam, Akbari Mohammad Esmael, Niazi Vahid, Karami Farshid, Rezvani Alireza, Ansarinejad Nafiseh, Abbasinia Masroor, Sarvari Gisoo, Zali Hakimeh, Talaie Ramin
Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2020 Winter;13(Suppl1):S18-S28.
Colorectal cancer (CRC) is a heterogeneous disease with various genetic and epigenetic factors leading to difficulties in response to both the therapy and drug resistance. Moreover, even in tumors with similar histopathological characteristics, different responses and molecular features could be observed because of the genetic basis and its interactions with the living environment. Through personalized medicine, we can classify patients into separate groups according to their genetic and epigenetic features and their susceptibility for a specific disease which could help with choosing the best therapeutic approach. In this review, genetic and epigenetic factors that cause heterogeneity in colorectal cancer are evaluated and proper drug administration in both chemotherapy and target therapy are suggested.
结直肠癌（CRC）是一种异质性疾病，存在多种遗传和表观遗传因素，导致其在治疗反应和耐药性方面存在困难。此外，即使在具有相似组织病理学特征的肿瘤中，由于遗传基础及其与生存环境的相互作用，也可能观察到不同的反应和分子特征。通过个性化医疗，我们可以根据患者的遗传和表观遗传特征以及他们对特定疾病的易感性将患者分为不同的组，这有助于选择最佳的治疗方法。在这篇综述中，评估了结直肠癌中导致异质性的遗传和表观遗传因素，并建议在化疗和靶向治疗中进行适当的药物给药。
